Exploiting virus-like particles as innovative vaccines against emerging viral infections

Journal of Microbiology

Volumn 55, Issue 3, 2017, Pages 220-230

  Jeong, Hotcherl ^a   Seong, Baik Lin ^b  

^a Ewha Womans University   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

downstream processes; emerging viruses; expression systems; vaccine design; virus like particles

Indexed keywords

VIRAL PROTEIN; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE;

CHEMISTRY; COMMUNICABLE DISEASES, EMERGING; DRUG DEVELOPMENT; HISTORY; IMMUNOLOGY; VACCINATION; VIROLOGY; VIRUS DISEASES;

ANTIBODIES, VIRAL; COMMUNICABLE DISEASES, EMERGING; DRUG DISCOVERY; HISTORY, 20TH CENTURY; VACCINATION; VACCINES, VIRUS-LIKE PARTICLE; VIRAL PROTEINS; VIRUS DISEASES;

EID: 85014020006     PISSN: 12258873     EISSN: 19763794     Source Type: Journal    
DOI: 10.1007/s12275-017-7058-3     Document Type: Review

References (105)

1. Akahata, W., Yang, Z.Y., Andersen, H., Sun, S., Holdaway, H.A., Kong, W.P., Lewis, M.G., Higgs, S., Rossmann, M.G., Rao, S., et al. 2010. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat. Med. 16, 334–338.
2. Andre, F.E., Booy, R., Bock, H.L., Clemens, J., Datta, S.K., John, T.J., Lee, B.W., Lolekha, S., Peltola, H., Ruff, T.A., et al. 2008. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull. World Health Organ. 86, 140–146.
3. Ashcroft, A.E., Lago, H., Macedo, J.M., Horn, W.T., Stonehouse, N.J., and Stockley, P.G. 2005. Engineering thermal stability in RNA phage capsids via disulphide bonds. J. Nanosci. Nanotechnol. 5, 2034–2041.
4. Ashley, C.E., Carnes, E.C., Phillips, G.K., Durfee, P.N., Buley, M.D., Lino, C.A., Padilla, D.P., Phillips, B., Carter, M.B., Willman, C.L., et al. 2011. Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles. ACS Nano. 5, 5729–5745.
5. Ausar, S.F., Foubert, T.R., Hudson, M.H., Vedvick, T.S., and Middaugh, C.R. 2006. Conformational stability and disassembly of Norwalk virus-like particles. Effect of pH and temperature. J. Biol. Chem. 281, 19478–19488.
6. Bachmann, M.F. and Jennings, G.T. 2010. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10, 787–796.
7. Bachmann, M.F., Rohrer, U.H., Kündig, T.M., Bürki, K., Hengartner, H., and Zinkernagel, R.M. 1993. The influence of antigen organization on B cell responsiveness. Science 262, 1448–1451.
8. Bachmann, M.F. and Zinkernagel, R.M. 1997. Neutralizing antiviral B cell responses. Annu. Rev. Immunol. 15, 235–270.
9. Bae, C.S., Yang, D.S., Chang, K.R., Seong, B.L., and Lee, J. 1998. Enhanced secretion of human granulocyte colony-stimulating factor directed by a novel hybrid fusion peptide from recombinant Saccharomyces cerevisiae at high cell concentration. Biotechnol Bioeng. 57, 600–609.
10. Billaud, J.N., Peterson, D., Barr, M., Chen, A., Sallberg, M., Garduno, F., Goldstein, P., McDowell, W., Hughes, J., Jones, J., et al. 2005. Combinatorial approach to hepadnavirus-like particle vaccine design. J. Virol. 79, 13656–13666.
11. Bowick, G.C. and McAuley, A.J. 2011. Vaccine and adjuvant design for emerging viruses: mutations, deletions, segments and signaling. Bioeng. Bugs 2, 129–135.
12. Bundy, B.C., Franciszkowicz, M.J., and Swartz, J.R. 2008. Escherichia coli-based cell-free synthesis of virus-like particles. Biotechnol. Bioeng. 100, 28–37.
13. Bundy, B.C. and Swartz, J.R. 2011. Efficient disulfide bond formation in virus-like particles. J. Biotechnol. 154, 230–239.
14. Carrillo-Tripp, M., Shepherd, C.M., Borelli, I.A., Venkataraman, S., Lander, G., Natarajan, P., Johnson, J.E., Brooks, C.L. 3rd, and Reddy, V.S. 2009. VIPERdb2: an enhanced and web API enabled relational database for structural virology. Nucleic Acids Res. 37(Database issue), D436–442.
15. Chackerian, B., Durfee, M.R., and Schiller, J.T. 2008. Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model. J. Immunol. 180, 5816–5825.
16. Chen, X.S., Casini, G., Harrison, S.C., and Garcea, R.L. 2001. Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1. J. Mol. Biol. 307, 173–182.
17. Chen, Q. and Lai, H. 2013. Plant-derived virus-like particles as vaccines. Hum. Vaccin Immunother. 9, 26–49.
18. Choi, S.I., Han, K.S., Kim, C.W., Ryu, K.S., Kim, B.H., Kim, K.H., Kim, S.I., Kang, T.H., Shin, H.C., Lim, K.H., et al. 2008. Protein solubility and folding enhancement by interaction with RNA. PLoS One 3, e2677.
19. Choi, S.I., Kwon, S., Son, A., Jeong, H., Kim, K.H., and Seong, B.L. 2013. Protein folding in vivo revisited. Curr. Protein Pept. Sci. 14, 721–733.
20. Choi, S.I., Ryu, K., and Seong, B.L. 2009. RNA-mediated chaperone type for de novo protein folding. RNA Biol. 6, 21–24.
21. Ding, Y., Chuan, Y.P., He, L., and Middelberg, A.P.J. 2010. Modeling the competition between aggregation and self-assembly during virus-like particle processing. Biotechnol. Bioeng. 107, 550–560.
22. Effio, C.L. and Hubbuch, J. 2015. Next generation vaccines and vectors: Designing downstream processes for recombinant proteinbased virus-like particles. Biotechnol. J. 10, 715–727.
23. Fernandes, F., Teixeira, A.P., Carinhas, N., Carrondo, M.J., and Alves, P.M. 2013. Insect cells as a production platform of complex viruslike particles. Expert Rev. Vaccines 12, 225–236.
24. Fiedler, J.D., Higginson, C., Hovlid, M.L., Kislukhin, A.A., Castillejos, A., Manzenrieder, F., Campbell, M.G., Voss, N.R., Potter, C.S., Carragher, B., et al. 2012. Engineered mutations change the structure and stability of a virus-like particle. Biomacromolecules 13, 2339–2348.
25. Galarza, J.M., Latham, T., and Cupo, A. 2005. Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol. 18, 365–372.
26. Giersing, B.K., Modjarrad, K., Kaslow, D.C., and Moorthy, V.S. 2016a. WHO Product Development for Vaccines Advisory Committee; WHO Product Development for Vaccines Product Development Advisory Committee. Report from the World Health Organization’s Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7-9th Sep 2015. Vaccine 34, 2865–2869.
27. Giersing, B.K., Modjarrad, K., Kaslow, D.C., Okwo-Bele, J.M., and Moorthy, V.S. 2016b. The 2016 Vaccine Development Pipeline: A special issue from the World Health Organization Product Development for Vaccine Advisory Committee (PDVAC). Vaccine 34, 2863–2864.
28. Grimes, J.M., Burroughs, J.N., Gouet, P., Diprose, J.M., Malby, R., Zié ntara, S., Mertens, P.P., and Stuart, D.I. 1998. The atomic structure of the bluetongue virus core. Nature 395, 470–478.
29. Gunther, S., Feldmann, H., Geisbert, T.W., Hensley, L.E., Rollin, P.E., Nichol, S.T., Stroher, U., Artsob, H., Peters, C.J., Ksiazek, T.G., et al. 2011. Management of accidental exposure to Ebola virus in the bios afety level 4 laboratory, Hamburg, Germany. J. Infect. Dis. 204, S785–S790.
30. Hall, A.J. 2012. Noroviruses: the perfect human pathogens? J. Infect. Dis. 205, 1622–1624.
31. Hall, A.J., Rosenthal, M., Gregoricus, N., Greene, S.A., Ferguson, J., Henao, O.L., Vinjé, J., Lopman, B.A., Parashar, U.D., and Widdowson, M.A. 2011. Incidence of acute gastroenteritis and role of norovirus, Georgia, USA, 2004–2005. Emerg. Infect. Dis. 17, 1381–1388.
32. Han, K.S., Kim, S.I., Choi, S.I., and Seong, B.L. 2005. N-Glycosylation of secretion enhancer peptide as influencing factor for the secretion of target proteins from Saccharomyces cerevisiae. Biochem. Biophys. Res. Commun. 337, 557–562.
33. Huhti, L., Blazevic, V., Nurminen, K., Koho, T., Hytö nen, V.P., and Vesikari, T. 2010. A comparison of methods for purification and concentration of norovirus GII-4 capsid virus-like particles. Arch. Virol. 155, 1855–1858.
34. Jennings, G.T. and Bachmann, M.F. 2008. The coming of age of virus-like particle vaccines. Biol. Chem. 389, 521–536.
35. Jiang, X., Wang, M., Graham, D.Y., and Estes, M.K. 1992. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J. Virol. 66, 6527–6532.
36. Kaczmarczyk, S.J., Sitaraman, K., Young, H.A., Hughes, S.H., and Chatterjee, D.K. 2011. Protein delivery using engineered viruslike particles. Proc. Natl. Acad. Sci. USA 108, 16998–17003.
37. Kang, S.M., Kim, M.C., and Compans, R.W. 2012. Virus-like particles as universal influenza vaccines. Expert Rev. Vaccines 11, 995–1007.
38. Kato, S., Kobayashi, K., Inoue, K., Kuramochi, M., Okada, T., Yaginuma, H., Morimoto, K., Shimada, T., Takada, M., and Kobayashi, K. 2011. A lentiviral strategy for highly efficient retrograde gene transfer by pseudotyping with fusion envelope glycoprotein. Hum. Gene Ther. 22, 197–206.
39. Kawano, M., Matsui, M., and Handa, H. 2013. SV40 virus-like particles as an effective delivery system and its application to a vaccine carrier. Expert Rev. Vaccines 12, 199–210.
40. Keller, S.A., Schwarz, K., Manolova, V., von Allmen, C.E., Kinzler, M.G., Bauer, M., Muntwiler, S., Saudan, P., and Bachmann, M.F. 2010. Innate signaling regulates cross-priming at the level of DClicensing and not antigen presentation. Eur. J. Immunol. 40, 103–112.
41. Keswani, R.K., Pozdol, I.M., and Pack, D.W. 2013. Design of hybrid lipid/retroviral-like particle gene delivery vectors. Mol. Pharm. 10, 1725–1735.
42. Kim, H.J. and Kim, H.J. 2017. Yeast as an expression system for producing virus-like particles: what factors do we need to consider? Lett. Appl. Microbiol. 64, 111–123.
43. Kissmann, J., Ausar, S.F., Foubert, T.R., Brock, J., Switzer, M.H., Detzi, E.J., Vedvick, T.S., and Middaugh, C.R. 2008. Physical stabilization of Norwalk virus-like particles. J. Pharm. Sci. 97, 4208–4218.
44. Koho, T., Mäntylä, T., Laurinmäki, P., Huhti, L., Butcher, S.J., Vesikari, T., Kulomaa, M.S., and Hytönen, V.P. 2012. Purification of norovirus-like particles (VLPs) by ion exchange chromatography. J. Virol. Methods 181, 6–11.
45. Kuroda, D., Shirai, H., Jacobson, M.P., and Nakamura, H. 2012. Computer-aided antibody design. Protein Eng. Des. Sel. 25, 507–521.
46. Kushnir, N., Streatfield, S.J., and Yusibov, V. 2012. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 31, 58–83.
47. Lai, H. and Chen, Q. 2012. Bioprocessing of plant derived virus-like particles of Norwalk virus capsid protein under current Good Manufacture Practice regulations. Plant Cell. Rep. 31, 573–584.
48. Lee, J., Choi, S.I., Jang, J.S., Jang, K., Moon, J.W., Bae, C.S., Yang, D.S., and Seong, B.L. 1999. Novel secretion system of recombinant Saccharomyces cerevisiae using an N-terminus residue of human IL-1 beta as secretion enhancer. Biotechnol. Prog. 15, 884–890.
49. Li, H.Y., Han, J.F., Qin, C.F., and Chen, R. 2013. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine 31, 3281–3287.
50. Lico, C., Chen, Q., and Santi, L. 2008. Viral vectors for production of recombinant proteins in plants. J. Cell. Physiol. 216, 366–377.
51. Link, A., Zabel, F., Schnetzler, Y., Titz, A., Brombacher, F., and Bachmann, M.F. 2012. Innate immunity mediates follicular transport of particulate but not soluble protein antigen. J. Immunol. 188, 3724–3733.
52. Liu, M.A., Wahren, B., and Karlsson Hedestam, G.B. 2006. DNA vaccines: recent developments and future possibilities. Hum. Gene Ther. 17, 1051–1061.
53. Ma, J.K.C., Barros, E., Bock, R., Christou, P., Dale, P.J., Dix, P.J., Fischer, R., Irwin, J., Mahoney, R., Pezzotti, M., et al. 2005. Molecular pharming for new drugs. EMBO Rep. 6, 593–599.
54. Mach, H., Volkin, D.B., Troutman, R.D., and Wang, B.E.I. 2006. Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs). J. Pharm. Sci. 95, 2195–2206.
55. Manolova, V., Flace, A., Bauer, M., Schwarz, K., Saudan, P., and Bachmann, M.F. 2008. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38, 1404–1413.
56. Marsian, J. and Lomonossoff, G.P. 2016. Molecular pharming -VLPs made in plants. Curr. Opin. Biotechnol. 37, 201–206.
57. Matic, S., Masenga, V., Poli, A., Rinaldi, R., Milne, R.G., Vecchiati, M., and Noris, E. 2012. Comparative analysis of recombinant Human Papillomavirus 8 L1 production in plants by a variety of expression systems and purification methods. Plant Biotechnol. J. 10, 410–421.
58. McCarthy, M.P., White, W.I., Palmer-Hill, F., Koenig, S., and Suzich, J.A. 1998. Quantitative disassembly and reassembly of human papillomavirus type 11 virus-like particles in vitro. J. Virol. 72, 32–41.
59. McGuigan, L.C., Stallard, V., Roos, J.M., and Payne, L.G. 1993. Recombinant-expressed virus-like particle pseudotypes as an approach to vaccine development. Vaccine 11, 675–678.
60. Mechtcheriakova, I.A., Eldarov, M.A., Nicholson, L., Shanks, M., Skryabin, K.G., and Lomonossoff, G.P. 2006. The use of viral vectors to produce hepatitis B virus core particles in plants. J. Virol. Methods 131, 10–15.
61. Münger, K., Baldwin, A., Edwards, K.M., Hayakawa, H., Nguyen, C.L., Owens, M., Grace, M., and Huh, K. 2004. Mechanisms of human papillomavirus-induced oncogenesis. J. Virol. 78, 11451–11460.
62. Pallister, J., Middleton, D., Wang, L.F., Klein, R., Haining, J., Robinson, R., Yamada, M., White, J., Payne, J., Feng, Y.R., et al. 2011. A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge. Vaccine 29, 5623–5630.
63. Palomares, L.A., Mena, J.A., and Ramírez, O.T. 2012. Simultaneous expression of recombinant proteins in the insect cell-baculovirus system: production of virus-like particles. Methods 56, 389–395.
64. Pankavich, S. and Ortoleva, P. 2012. Multiscaling for systems with a broad continuum of characteristic lengths and times: Structural transitions in nanocomposites. J. Math. Phys. 51, 63303.
65. Patel, M.M., Hall, A.J., Vinjé, J., and Parashar, U.D. 2009. Noroviruses: a comprehensive review. J. Clin. Virol. 44, 1–8.
66. Paul, M., van Dolleweerd, C., Drake, P.M., Reljic, R., Thangaraj, H., Barbi, T., Stylianou, E., Pepponi, I., Both, L., Hehle, V., et al. 2011. Molecular Pharming: future targets and aspirations. Hum. Vaccin. 7, 375–382.
67. Peacey, M., Wilson, S., Baird, M.A., and Ward, V.K. 2007. Versatile RHDV virus-like particles: incorporation of antigens by genetic modification and chemical conjugation. Biotechnol. Bioeng. 98, 968–977.
68. Pei, H., Liu, J., Cheng, Y., Sun, C., Wang, C., Lu, Y., Ding, J., Zhou, J., and Xiang, H. 2005. Expression of SARS-coronavirus nucleocapsid protein in Escherichia coli and Lactococcus lactis for serodiagnosis and mucosal vaccination. Appl. Microbiol. Biotechnol. 68, 220–227.
69. Peyret, H., Gehin, A., Thuenemann, E.C., Blond, D., El Turabi, A., Beales, L., Clarke, D., Gilbert, R.J., Fry, E.E., Stuart, D.I., et al. 2015. Tandem fusion of hepatitis B core antigen allows assembly of virus-like particles in bacteria and plants with enhanced capacity to accommodate foreign proteins. PLoS One 10, e0120751.
70. Plummer, E.M. and Manchester, M. 2011. Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design. Wiley Interdiscip. Rev. Nanomed Nanobiotechnol. 3, 174–196.
71. Powell, K. 2004. DNA vaccines — back in the saddle again? Nat. Biotechnol. 22, 799–801.
72. Prasad, B.V., Hardy, M.E., Dokland, T., Bella, J., Rossmann, M.G., and Estes, M.K. 1999. X-ray crystallographic structure of the Norwalk virus capsid. Science 286, 287–290.
73. Ramqvist, T., Andreasson, K., and Dalianis, T. 2007. Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer. Expert. Opin. Biol. Ther. 7, 997–1007.
74. Rathore, A.S. and Winkle, H. 2009. Quality by design for biopharmaceuticals. Nat. Biotechnol. 27, 26–34.
75. Ren, Y., Wong, S.M., and Lim, L.Y. 2006. In vitro-reassembled plant virus-like particles for loading of polyacids. J. Gen. Virol. 87, 2749–2754.
76. Rodríguez-Limas, W.A., Flores-Samaniego, B., de la Mora, G., Ramírez, O.T., and Palomares, L.A. 2011. Molecular and process design for rotavirus-like particle production in Saccharomyces cerevisiae. Microb. Cell Fact. 10, 33.
77. Roldão, A., Mellado, M.C., Lima, J.C., Carrondo, M.J., Alves, P.M., and Oliveira, R. 2012. On the effect of thermodynamic equilibrium on the assembly efficiency of complex multi-layered viruslike particles (VLP): The case of rotavirus VLP. PLoS Comput. Biol. 8, e1002367.
78. Rybicki, E.P. 2014. Plant-based vaccines against viruses. Virol. J. 11, 205.
79. Sabchareon, A., Wallace, D., Sirivichayakul, C., Limkittikul, K., Chanthavanich, P., Suvannadabba, S., Jiwariyavej, V., Dulyachai, W., Pengsaa, K., Wartel, T.A., et al. 2012. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380, 1559–1567.
80. Salunke, D.M., Caspar, D.L., and Garcea, R.L. 1986. Self-assembly of purified polyomavirus capsid protein VP1. Cell 46, 895–904.
81. Sánchez-Rodríguez, S.P., Münch-Anguiano, L., Echeverría, O., Vázquez-Nin, G., Mora-Pale, M., Dordick, J.S., and Bustos-Jaimes, I. 2012. Human parvovirus B19 virus-like particles: In vitro assembly and stability. Biochimie 94, 870–888.
82. Scotti, N. and Rybicki, E.P. 2013. Virus-like particles produced in plants as potential vaccines. Expert Rev. Vaccines 12, 211–224.
83. Seow, Y. and Wood, M.J. 2009. Biological gene delivery vehicles: beyond viral vectors. Mol. Ther. 17, 767–777.
84. Shapshak, P., Chiappelli, F., Somboonwit, C., and Sinnott, J. 2011. The influenza pandemic of 2009: lessons and implications. Mol. Diagn. Ther. 15, 63–81.
85. Shi, L., Sanyal, G., Ni, A., Luo, Z., Doshna, S., Wang, B., Graham, T.L., Wang, N., and Volkin, D.B. 2005. Stabilization of human papillomavirus virus-like particles by non-ionic surfactants. J. Pharm. Sci. 94, 1538–1551.
86. Søborg, C., Mølbak, K., Doherty, T.M., Ulleryd, P., Brooks, T., Coenen, C., and van der Zeijst, B. 2009. Vaccines in a hurry. Vaccine 27, 3295–3298.
87. Steel, J., Lowen, A.C., Wang, T.T., Yondola, M., Gao, Q., Haye, K., Garcia-Sastre, A., and Palese, P. 2010. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 1, e00018-10.
88. Storni, T., Lechner, F., Erdmann, I., Bächi, T., Jegerlehner, A., Dumrese, T., Kündig, T.M., Ruedl, C., and Bachmann, M.F. 2002. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with viruslike particles. J. Immunol. 168, 2880–2886.
89. Taylor, R.M. 2009. Production and downstream processing of norovirus virus-like particles. Presented at: 12th International Meeting, Baculovirus and Insect Cell Culture. San Antonio, TX, USA.
90. Turley, C.B., Rupp, R.E., Johnson, C., Taylor, D.N., Wolfson, J., Tussey, L., Kavita, U., Stanberry, L., and Shaw, A. 2011. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 29, 5145–5152.
91. Twyman, R.M., Stoger, E., Schillberg, S., Christou, P., and Fischer, R. 2003. Molecular farming in plants: host systems and expression technology. Trends Biotechnol. 21, 570–578.
92. U.S. Food and Drug Administration, CBER. 1999. Guidance for Industry Information and Establishment Description Information for a Vaccine.
93. Wang, T.T., Tan, G.S., Hai, R., Pica, N., Petersen, E., Moran, T.M., and Palese, P. 2010. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog. 6, e1000796.
94. Whitacre, D.C., Lee, B.O., and Milich, D.R. 2009. Use of hepadnavirus core proteins as vaccine platforms. Expert Rev. Vaccines 8, 1565–1573.
95. World Health Organization. 2006. Guidelines to assure the quality, safety and efficacy of recombinant human papillomavirus viruslike particle vaccines, pp. 23–27.
96. Wynne, S.A., Crowther, R.A., and Leslie, A.G. 1999. The crystal structure of the human hepatitis B virus capsid. Mol. Cell. 3, 771–780.
97. Xing, L., Li, T.C., Mayazaki, N., Simon, M.N., Wall, J.S., Moore, M., Wang, C.Y., Takeda, N., Wakita, T., Miyamura, T., et al. 2010. Structure of hepatitis E virion-sized particle reveals an RNAdependent viral assembly pathway. J. Biol. Chem. 285, 33175–33183.
98. York, I. and Donis, R.O. 2013. The 2009 pandemic influenza virus: where did it come from, where is it now, and where is it going? Curr. Top. Microbiol. Immunol. 370, 241–257.
99. Yu, Z., Reid, J.C., and Yang, Y.P. 2013. Utilizing dynamic light scattering as a process analytical technology for protein folding and aggregation monitoring in vaccine manufacturing. J. Pharm. Sci. 102, 4284–4290.
100. Zabel, F., Kündig, T.M., and Bachmann, M.F. 2013. Virus-induced humoral immunity: on how B cell responses are initiated. Curr. Opin. Virol. 3, 357–362.
101. Zeltins, A. 2013. Construction and characterization of virus-like particles: a review. Mol. Biotechnol. 53, 92–107.
102. Zhang, L., Tang, R., Bai, S., Connors, N.K., Lua, L.H., Chuan, Y.P., Middelberg, A.P., and Sun, Y. 2013. Molecular energetics in the capsomere of virus-like particle revealed by molecular dynamics simulations. J. Phys. Chem. B. 117, 5411–5421.
103. Zhang, L., Tang, R., Bai, S., Connors, N.K., Lua, L.H., Chuan, Y.P., Middelberg, A.P., and Sun, Y. 2014. Energetic changes caused by antigenic module insertion in a virus-like particle revealed by experiment and molecular dynamics simulations. PLoS One 9, e107313.
104. Zhao, Q., Allen, M.J., Wang, Y., Wang, B., Wang, N., Shi, L., and Sitrin, R.D. 2012a. Disassembly and reassembly improves morphology and thermal stability of human papillomavirus type 16 virus-like particles. Nanomedicine 8, 1182–1189.
105. Zhao, Q., Modis, Y., High, K., Towne, V., Meng, Y., Wang, Y., Alexandroff, J., Brown, M., Carragher, B., Potter, C.S., et al. 2012b. Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity. Virol. J. 9, 52.